Abstract:
Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.
Abstract:
The invention relates to the treatment of an inflammatory or immune disorder with a pharmaceutical composition including methylsulphonylmethane, glucosamine and glycine or pharmaceutically acceptable salts or derivatives of these compounds.
Abstract:
Изобретение относится к фармакологии, медицине, ветеринарии и к фармацевтической промышленности, в частности, к способу получения оригинальных композитных антимикробных препаратов для парентерального применения, которые обладают повышенной терапевтической эффективностью при лечении тяжёлых форм туберкулёза и других инфекционно-воспалительных заболеваний. Предложенная фармацевтическая композиция содержат в качестве действующего вещества антибиотик-аминогликозид или капреомицин и высокодисперсный наноструктурированный диоксид кремния. Заявляемый способ получения фармацевтической композиции заключается в смешивании субстанции антибиотика-аминогликозида или капреомицина с высокодисперсным наноструктурированным диоксидом кремния отличающийся тем, что смесь вышеуказанных веществ в соотношениях от 10: 1 до 70:1 по весу, соответственно, подвергают механической обработке путем ударно-истирающих воздействий для увеличения весовой доли мелкодисперсной фракции. Полученную смесь используют для приготовления инъекционных растворов.
Abstract:
Provided is a compound represented by the formula (I): wherein R1 represents R5=N- (R5 represents a saccharide residue) or (R4 represents a mono- or polyethylene glycol residue); each of R2 and R3, whether identical or not, represents a hydrocarbon group having 1-30 carbon atoms; and n represents 0 or 1.
Abstract:
La présente invention concerne des composés de formule :(I) dans laquelle : R 1 ≠ 2-désoxystreptamine et ses dérivés substitués aux positions 5 et/ou 6; R 2 et R 6 , identiques ou différents, représentent une fonction aminé primaire, secondaire ou tertiaire : NH 2 , NHR, NRR' avec R et R' = alkyl, aryl, cyclique ou non, substitué ou non; - OR 3 et OR 4 forment des fonctions alcool, éther, ester, carbonate, carbamate, sulfonate ou sulfamate; et. si R 3 = R 4, alors R 3 et R 4 ≠ H;. si R 3 = H, alors R 4 ≠ H et R 1 ≠ OH; et. si R 4 = H, alors R 3 ≠H et R 1 ≠OH;. si Ri= OH, alors R3 et R4≠ H, et si Ri=OR 5, alors R 3 et/ou R 4 et/ou R 5 n'est pas un sucre ou un polysaccharide; ainsi que leur utilisation comme médicaments et plus précisément comme antibiotiques.
Abstract:
The present document describes methods of use of photoactivated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.
Abstract:
The present invention relates to DNA ligands capable of binding to aflatoxin and zearalenone. The invention relates also to methods for determining the presence and concentration of aflatoxin and zearalenone in samples such as agricultural and food products, and to methods for removing or reducing the level of aflatoxin and zearalenone in samples such as agricultural and food products. The invention further relates to methods for identifying DNA ligands capable of binding to aflatoxin and zearalenone. The invention further relates to new DNA sequences.
Abstract:
Glucosamine supplements are widely used for the treatment of osteoarthritis. However, glucosamine has poor and variable gastrointestinal absorption although it is usually taken orally. The current invention provides new formulations and/or methods that could increase the plasma concentration by 1.3 to 4 times after oral administration of glucosamine with an additional absorption enhancer. In the current invention, chitosans and cyclodextrins were identified as suitable absorption enhancers for glucosamine.